{"id":"acalabrutinib-treatment-a","safety":{"commonSideEffects":[{"rate":"22%","effect":"Headache"},{"rate":"21%","effect":"Diarrhea"},{"rate":"20%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4747506","moleculeType":"Unknown","molecularWeight":"465.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Acalabrutinib is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), a key component in the B-cell receptor signaling complex.","oneSentence":"BTK inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:52:04.241Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT02477696","phase":"PHASE3","title":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2015-07-28","conditions":"Chronic Lymphocytic Leukemia","enrollment":533},{"nctId":"NCT05388006","phase":"PHASE2","title":"Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-01-05","conditions":"Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma","enrollment":27},{"nctId":"NCT02717611","phase":"PHASE2","title":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2016-03-08","conditions":"Chronic Lymphocytic Leukemia","enrollment":60},{"nctId":"NCT06548152","phase":"","title":"AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-28","conditions":"Chronic Lymphocytic Leukemia","enrollment":120},{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":"Liver Lymphoma, Mantle Cell Lymphoma","enrollment":360},{"nctId":"NCT06211413","phase":"","title":"Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors","status":"ENROLLING_BY_INVITATION","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2024-02-07","conditions":"Chronic Lymphocytic Leukemia, Atrial Fibrillation, Hypertension","enrollment":50},{"nctId":"NCT05557695","phase":"","title":"Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-10-17","conditions":"Chronic Lymphocytic Leukemia, CLL","enrollment":350},{"nctId":"NCT05437250","phase":"","title":"National Acalabrutinib Observational Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-13","conditions":"Chronic Lymphocytic Leukemia","enrollment":350},{"nctId":"NCT05495464","phase":"EARLY_PHASE1","title":"A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-11-18","conditions":"Lymphoma, Mantle Cell Lymphoma","enrollment":22},{"nctId":"NCT04624633","phase":"PHASE2","title":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer R. Brown, MD, PhD","startDate":"2020-12-15","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia","enrollment":29},{"nctId":"NCT06524375","phase":"PHASE2","title":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2024-08-09","conditions":"Chronic Lymphocytic Leukemia","enrollment":118},{"nctId":"NCT04169737","phase":"PHASE2","title":"Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-29","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":168},{"nctId":"NCT06651970","phase":"PHASE4","title":"Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-02-04","conditions":"Chronic Lymphocytic Leukaemia, Heart Failure","enrollment":60},{"nctId":"NCT04002947","phase":"PHASE2","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-05","conditions":"Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL","enrollment":132},{"nctId":"NCT02972840","phase":"PHASE3","title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-04-05","conditions":"Lymphoma, Mantle Cell","enrollment":635},{"nctId":"NCT03580928","phase":"PHASE2","title":"Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-08-07","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":72},{"nctId":"NCT03516617","phase":"PHASE2","title":"Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-09-10","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":120},{"nctId":"NCT02029443","phase":"PHASE1, PHASE2","title":"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2014-01-30","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":306},{"nctId":"NCT04560322","phase":"PHASE2","title":"Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-10-19","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":40},{"nctId":"NCT04624906","phase":"PHASE2","title":"Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-03-02","conditions":"Waldenstrom Macroglobulinemia","enrollment":63},{"nctId":"NCT05583149","phase":"PHASE2","title":"Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Patrick C. Johnson, MD","startDate":"2023-03-01","conditions":"Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL","enrollment":28},{"nctId":"NCT04116437","phase":"PHASE2","title":"Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-10-15","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma","enrollment":96},{"nctId":"NCT03740529","phase":"PHASE1, PHASE2","title":"A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2019-03-15","conditions":"Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma","enrollment":803},{"nctId":"NCT04855695","phase":"PHASE1, PHASE2","title":"Avo In R/R And Previously Untreated MCL","status":"RECRUITING","sponsor":"Austin I Kim","startDate":"2021-07-02","conditions":"Mantle Cell Lymphoma, Refractory Lymphoma","enrollment":72},{"nctId":"NCT07024706","phase":"PHASE2","title":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-30","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":80},{"nctId":"NCT02717624","phase":"PHASE1","title":"A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2016-04-20","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":72},{"nctId":"NCT02337829","phase":"PHASE2","title":"Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":48},{"nctId":"NCT07014917","phase":"PHASE2","title":"Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL","status":"RECRUITING","sponsor":"Zulfa Omer","startDate":"2025-12-05","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, CLL Variant","enrollment":62},{"nctId":"NCT04523428","phase":"PHASE2","title":"REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2020-12-23","conditions":"CLL/SLL","enrollment":60},{"nctId":"NCT06054776","phase":"PHASE2","title":"Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-12-02","conditions":"Mantle Cell Lymphoma","enrollment":40},{"nctId":"NCT04604067","phase":"PHASE2","title":"Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2021-06-25","conditions":"Diffuse Large B-cell Lymphoma","enrollment":260},{"nctId":"NCT04505254","phase":"PHASE2","title":"Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-25","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":60},{"nctId":"NCT04155710","phase":"PHASE1","title":"Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL","status":"COMPLETED","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2020-02-19","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":7},{"nctId":"NCT05952024","phase":"PHASE2","title":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02296918","phase":"PHASE1","title":"Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-12-22","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia","enrollment":69},{"nctId":"NCT07052695","phase":"PHASE1, PHASE2","title":"Mosunetuzumab for CLL MRD Clearance","status":"RECRUITING","sponsor":"Inhye Ahn","startDate":"2025-11-24","conditions":"Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":40},{"nctId":"NCT02362035","phase":"PHASE1, PHASE2","title":"ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-02-20","conditions":"Follicular Lymphoma (FL), CLL, Small Lymphocytic Lymphoma (SLL)","enrollment":161},{"nctId":"NCT02328014","phase":"PHASE1, PHASE2","title":"Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-12-20","conditions":"Non-Hodgkins Lymphoma, Multiple Myeloma, B-All","enrollment":40},{"nctId":"NCT05065554","phase":"PHASE2","title":"ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shayna Sarosiek, MD","startDate":"2021-11-16","conditions":"IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral","enrollment":12},{"nctId":"NCT07174141","phase":"","title":"Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2025-11-28","conditions":"Treatment With Second-generation Bruton's Tyrosine Kinase Inhibitors (Acalabrutinib, Zanubrutinib)","enrollment":100},{"nctId":"NCT04963946","phase":"PHASE2","title":"STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2021-10-18","conditions":"Untreated Chronic Lymphocytic Leukemia","enrollment":160},{"nctId":"NCT05645172","phase":"","title":"Retention Rate of Acalabrutinib in a Non-interventional Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-12","conditions":"Chronic Lymphocytic Leukaemia (CLL)","enrollment":137},{"nctId":"NCT04008706","phase":"PHASE3","title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-09-17","conditions":"Chronic Lymphocytic Leukemia","enrollment":552},{"nctId":"NCT04484012","phase":"PHASE2","title":"Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-12-31","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":36},{"nctId":"NCT06958705","phase":"PHASE2","title":"Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-01","conditions":"Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)","enrollment":79},{"nctId":"NCT03128879","phase":"PHASE2","title":"Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-06-16","conditions":"Chronic Lymphocytic Leukemia","enrollment":90},{"nctId":"NCT04189757","phase":"PHASE2","title":"Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-07","conditions":"Mantle Cell Lymphoma","enrollment":9},{"nctId":"NCT04765111","phase":"PHASE2","title":"Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-06-30","conditions":"Mantle Cell Lymphoma","enrollment":53},{"nctId":"NCT05943496","phase":"PHASE1","title":"Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-10-02","conditions":"Chronic Lymphocytic Leukemia","enrollment":27},{"nctId":"NCT04978584","phase":"PHASE2","title":"Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-03","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":62},{"nctId":"NCT05951959","phase":"PHASE2","title":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-13","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":108},{"nctId":"NCT06520098","phase":"PHASE2","title":"A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-10-01","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":100},{"nctId":"NCT05643235","phase":"NA","title":"Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2023-01-01","conditions":"Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest","enrollment":50},{"nctId":"NCT03162536","phase":"PHASE1, PHASE2","title":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2017-06-26","conditions":"Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia","enrollment":190},{"nctId":"NCT04722172","phase":"PHASE2","title":"A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-05-21","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":55},{"nctId":"NCT02475681","phase":"PHASE3","title":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2015-06-26","conditions":"Chronic Lymphocytic Leukemia","enrollment":535},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT02157324","phase":"PHASE1","title":"Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2014-08-18","conditions":"Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT04546620","phase":"PHASE2","title":"Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2021-10-19","conditions":"Diffuse Large B Cell Lymphoma","enrollment":453},{"nctId":"NCT04883749","phase":"PHASE2","title":"Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2021-06-01","conditions":"Chronic Lymphoid Leukemia","enrollment":53},{"nctId":"NCT03863184","phase":"PHASE2","title":"Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2019-10-11","conditions":"Mantle Cell Lymphoma","enrollment":37},{"nctId":"NCT06839872","phase":"PHASE2","title":"A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2025-06-30","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":""},{"nctId":"NCT06846489","phase":"PHASE2","title":"Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-14","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":50},{"nctId":"NCT04189952","phase":"PHASE2","title":"Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2020-09-22","conditions":"Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia","enrollment":2},{"nctId":"NCT04662255","phase":"PHASE3","title":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-04-08","conditions":"Lymphoma, Mantle-Cell","enrollment":500},{"nctId":"NCT04685915","phase":"PHASE2","title":"Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL","status":"WITHDRAWN","sponsor":"Inhye Ahn","startDate":"2021-02-18","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":""},{"nctId":"NCT04402138","phase":"PHASE2","title":"Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2020-08-07","conditions":"Mantle Cell Lymphoma","enrollment":15},{"nctId":"NCT03623373","phase":"PHASE2","title":"Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-11-29","conditions":"Mantle Cell Lymphoma","enrollment":13},{"nctId":"NCT05517265","phase":"","title":"Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)","status":"ACTIVE_NOT_RECRUITING","sponsor":"iOMEDICO AG","startDate":"2022-10-12","conditions":"CLL","enrollment":45},{"nctId":"NCT04657094","phase":"PHASE2","title":"Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-03-16","conditions":"Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":4},{"nctId":"NCT04666038","phase":"PHASE3","title":"Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-03-09","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":238},{"nctId":"NCT04630756","phase":"PHASE1, PHASE2","title":"AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-02-17","conditions":"Advanced Haematological Malignancies","enrollment":40},{"nctId":"NCT04404088","phase":"PHASE2","title":"Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-16","conditions":"Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma","enrollment":60},{"nctId":"NCT04178798","phase":"PHASE3","title":"Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-12-09","conditions":"Chronic Lymphocytic Leukemia- Binet Staging System","enrollment":22},{"nctId":"NCT04419389","phase":"PHASE1, PHASE2","title":"APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)","status":"TERMINATED","sponsor":"Aprea Therapeutics","startDate":"2021-03-02","conditions":"Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":1},{"nctId":"NCT04646395","phase":"PHASE2","title":"Study of Acalabrutinib and Tafasitamab in MZL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2021-10-20","conditions":"Marginal Zone Lymphoma","enrollment":26},{"nctId":"NCT06767891","phase":"","title":"Real-world Study of Acalabrutinib","status":"ENROLLING_BY_INVITATION","sponsor":"Ruijin Hospital","startDate":"2024-07-02","conditions":"MCL, CLL","enrollment":200},{"nctId":"NCT03787264","phase":"PHASE2","title":"Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2019-01-14","conditions":"Chronic Lymphoid Leukemia","enrollment":46},{"nctId":"NCT02112526","phase":"PHASE1","title":"Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-08-07","conditions":"Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)","enrollment":21},{"nctId":"NCT04783415","phase":"PHASE2","title":"Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-03-26","conditions":"Mantle Cell Lymphoma","enrollment":12},{"nctId":"NCT05521178","phase":"","title":"Cardiotoxicities in Patients Receiving BTKi","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":""},{"nctId":"NCT03788291","phase":"PHASE2","title":"Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2019-03-25","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":39},{"nctId":"NCT06319456","phase":"PHASE3","title":"A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-04-07","conditions":"CLL/SLL","enrollment":344},{"nctId":"NCT05950997","phase":"NA","title":"A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-16","conditions":"Chronic Lymphocytic Leukemia","enrollment":89},{"nctId":"NCT04626791","phase":"PHASE2","title":"Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2021-08-03","conditions":"Mantle Cell Lymphoma","enrollment":45},{"nctId":"NCT03868722","phase":"PHASE2, PHASE3","title":"Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2019-10-11","conditions":"CLL","enrollment":212},{"nctId":"NCT03571308","phase":"PHASE1, PHASE2","title":"A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2017-06-02","conditions":"Non Hodgkin Lymphoma","enrollment":39},{"nctId":"NCT06029166","phase":"NA","title":"Subcutaneous Cardiac Monitoring of Patients With BTK Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Caen","startDate":"2023-10-01","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT05205252","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.","status":"WITHDRAWN","sponsor":"Epizyme, Inc.","startDate":"2021-12-22","conditions":"Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy","enrollment":""},{"nctId":"NCT03702231","phase":"PHASE2","title":"Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-12-07","conditions":"Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL)","enrollment":116},{"nctId":"NCT03219047","phase":"EARLY_PHASE1","title":"Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-12-20","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":1},{"nctId":"NCT04016805","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2019-08-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":41},{"nctId":"NCT03899337","phase":"PHASE2","title":"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-07-23","conditions":"Richter Syndrome","enrollment":105},{"nctId":"NCT03527147","phase":"PHASE1","title":"Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2018-06-19","conditions":"NHL, DLBCL, Non-hodgkin's Lymphoma","enrollment":30},{"nctId":"NCT03736616","phase":"PHASE2","title":"Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL","status":"UNKNOWN","sponsor":"Swedish Medical Center","startDate":"2019-08-16","conditions":"Diffuse Large B Cell Lymphoma","enrollment":47},{"nctId":"NCT04768985","phase":"PHASE1","title":"Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-02-25","conditions":"Bioequivalence","enrollment":66},{"nctId":"NCT04836832","phase":"PHASE1","title":"Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"Narendranath Epperla","startDate":"2022-07-01","conditions":"Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma","enrollment":""},{"nctId":"NCT04660045","phase":"PHASE2","title":"Early Intervention With Acalabrutinib in Patients With High Risk CLL","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2022-05","conditions":"Chronic Lymphocytic Leukemia, CLL/SLL","enrollment":""},{"nctId":"NCT03685708","phase":"PHASE2","title":"HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-12-07","conditions":"Hepatitis, Safety and Tolerability","enrollment":78},{"nctId":"NCT05140096","phase":"PHASE1","title":"A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2020-01-03","conditions":"Healthy Volunteers","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AT"],"phase":"phase_1","status":"active","brandName":"Acalabrutinib Treatment A","genericName":"Acalabrutinib Treatment A","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BTK inhibitor Used for Chronic lymphocytic leukemia, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}